Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Azacitidine, Venetoclax and Pevonedistat in Adults With Newly Diagnosed Secondary or Therapy-Related AML

NCT03862157 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03862157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03862157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Azacitidine, Venetoclax and Pevonedistat in Adults With Newly Diagnosed Secondary or Therapy-Related AML
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 27, 2019
Completion date
January 31, 2027
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, atypical chronic myeloid leukemia, bcr-abl1 negative, chronic eosinophilic leukemia, not otherwise specified, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, essential thrombocythemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis, myelodysplastic/myeloproliferative neoplasm, unclassifiable, myeloid neoplasm, myeloproliferative neoplasm, myeloproliferative neoplasm, unclassifiable, overt primary myelofibrosis, polycythemia vera, polycythemia vera, post-polycythemic myelofibrosis phase, prefibrotic/early primary myelofibrosis